ASCO preview, EpCAM, Rocket & Hong Kong IPOs — a BioCentury podcast

A bispecific antibody from Merus features in BioCentury’s ASCO spotlight

Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling.

On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Phase II data from Merus N.V. (NASDAQ:MRUS) for petosemtamab as they preview the American Society of Clinical Oncology’s upcoming annual meeting, which kicks off Friday. 

The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. 

Finally, the team previews BioCentury’s second annual Grand Rounds R&D meeting, which takes place next week in Chicago.

This episode of the BioCentury This Week podcast is brought to you by Jeito Capital.